The goal of the study was to assess the effect of cannabidiol (CBD) on pet owner perception of chronically anxious dogs on their overall anxiety using a double-blinded, placebo-controlled, crossover model. Fifty-two dogs qualified as having mild to moderate chronic anxiety and were either assigned to 5 mg/kg BW CBD or a placebo provided orally once per day for 90 days for phase 1. After a 30-day washout period, dogs that remained in the study swapped treatments (CBD to Placebo, Placebo to CBD), and began phase 2 for 90 days. Forty concluded the study with only minor deviations. At every visit (days 0, 45, 90, 120, 165 and 210), physical exams, blood collections (for CBC, chemistry and plasma CBD), an abbreviated Canine Behavioral Assessment and Research Questionnaire (C-BARQ), and pet owner perception of their dog’s anxiety were completed. Adverse events were recorded. While physical exams remained the same among treatments, vocalization altered within the placebo treatment (p = 0.02). Plasma CBD revealed a large variation among dogs. There was no treatment effect on alanine aminotransferase, but alkaline phosphatase was elevated over time when supplemented with CBD, as expected, with averages below the upper reference limits. No significant treatment effects were found for any subscale in the modified C-BARQ; however, most subscales had a time effect (P < 0.001), indicating that pet owners perceived their dogs as being less anxious regardless of treatment. Future work on objective data, including stress-related biomarkers, may help elucidate whether there is any effect of CBD on canine anxiety.
扫码关注我们
求助内容:
应助结果提醒方式:
